Advertisement

Ads Placeholder
Loading...

Lysogene S.A.

LYS.PAEURONEXT
Healthcare
Biotechnology
0.28
0.00(0.00%)
U.S. Market opens in 54h 36m

Lysogene S.A. Fundamental Analysis

Lysogene S.A. (LYS.PA) shows weak financial fundamentals with a PE ratio of -0.34, profit margin of -3.66%, and ROE of -11.30%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position261.56%
PEG Ratio-0.00

Areas of Concern

ROE-11.30%
Operating Margin-3.56%
We analyze LYS.PA's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1696.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1696.6/100

We analyze LYS.PA's fundamental strength across five key dimensions:

Efficiency Score

Weak

LYS.PA struggles to generate sufficient returns from assets.

ROA > 10%
-69.12%

Valuation Score

Excellent

LYS.PA trades at attractive valuation levels.

PE < 25
-0.34
PEG Ratio < 2
-0.00

Growth Score

Weak

LYS.PA faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

LYS.PA maintains a strong and stable balance sheet.

Debt/Equity < 1
-2.26
Current Ratio > 1
1.21

Profitability Score

Weak

LYS.PA struggles to sustain strong margins.

ROE > 15%
-1129.83%
Net Margin ≥ 15%
-3.66%
Positive Free Cash Flow
No

Key Financial Metrics

Is LYS.PA Expensive or Cheap?

P/E Ratio

LYS.PA trades at -0.34 times earnings. This suggests potential undervaluation.

-0.34

PEG Ratio

When adjusting for growth, LYS.PA's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values Lysogene S.A. at -1.08 times its book value. This may indicate undervaluation.

-1.08

EV/EBITDA

Enterprise value stands at -0.55 times EBITDA. This is generally considered low.

-0.55

How Well Does LYS.PA Make Money?

Net Profit Margin

For every $100 in sales, Lysogene S.A. keeps $-3.66 as profit after all expenses.

-3.66%

Operating Margin

Core operations generate -3.56 in profit for every $100 in revenue, before interest and taxes.

-3.56%

ROE

Management delivers $-11.30 in profit for every $100 of shareholder equity.

-11.30%

ROA

Lysogene S.A. generates $-69.12 in profit for every $100 in assets, demonstrating efficient asset deployment.

-69.12%

Following the Money - Real Cash Generation

Operating Cash Flow

Lysogene S.A. generates limited operating cash flow of $-15.15M, signaling weaker underlying cash strength.

$-15.15M

Free Cash Flow

Lysogene S.A. generates weak or negative free cash flow of $-15.45M, restricting financial flexibility.

$-15.45M

FCF Per Share

Each share generates $-0.87 in free cash annually.

$-0.87

FCF Yield

LYS.PA converts -2.98% of its market value into free cash.

-2.98%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.34

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

-1.08

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.33

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-2.26

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.21

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-11.30

vs 25 benchmark

ROA

Return on assets percentage

-0.69

vs 25 benchmark

ROCE

Return on capital employed

-2.52

vs 25 benchmark

How LYS.PA Stacks Against Its Sector Peers

MetricLYS.PA ValueSector AveragePerformance
P/E Ratio-0.3428.45 Better (Cheaper)
ROE-1129.83%763.00% Weak
Net Margin-366.42%-45265.00% (disorted) Weak
Debt/Equity-2.260.34 Strong (Low Leverage)
Current Ratio1.212795.60 Neutral
ROA-69.12%-16588.00% (disorted) Weak

LYS.PA outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Lysogene S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ